Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.64 |
| ▸ | HTR2A | P28223 | 14/20 | 0.64 |
| ▸ | DRD2 | P14416 | 10/20 | 0.59 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.57 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.57 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.57 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.57 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.57 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.57 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995952 | 0.95 | DRD3 (0.59) | DRD3HTR2ADRD2PRKAB2PRKAG1 | |
| SCHEMBL230299 | 0.92 | HTR2A (0.55) | DRD3HTR2ADRD2PRKAB2PRKAG1 | |
| SCHEMBL228055 | 0.92 | HTR2A (0.65) | DRD3HTR2ADRD2 | |
| SCHEMBL227201 | 0.92 | DRD3 (0.60) | DRD3HTR2ADRD2 | |
| SCHEMBL229741 | 0.92 | HTR2A (0.65) | DRD3HTR2ADRD2 | |
| SCHEMBL229123 | 0.91 | HTR2A (0.54) | DRD3HTR2ADRD2PRKAB2PRKAG1 | |
| SCHEMBL251440 | 0.90 | HTR2A (0.65) | DRD3HTR2ADRD2 | |
| SCHEMBL228853 | 0.89 | HTR2A (0.52) | DRD3HTR2ADRD2PRKAB2PRKAG1 | |
| SCHEMBL230363 | 0.87 | DRD2 (0.62) | DRD3HTR2ADRD2 | |
| SCHEMBL228637 | 0.87 | HTR2A (0.64) | DRD3HTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | DRD3 18/4885HTR2A 1/4885DRD2 16/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | DRD3 18/4885HTR2A 1/4885DRD2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.